Brain ageing in schizophrenia: evidence from 26 international cohorts via the ENIGMA Schizophrenia consortium

0567044 - ÚI 2024 RIV GB eng J - Journal Article
Constantinides, C. - Han, L. K. M. - Alloza, C. - Tomeček, David … Total 93 authors
Brain ageing in schizophrenia: evidence from 26 international cohorts via the ENIGMA Schizophrenia consortium.
Molecular Psychiatry. Roč. 28, č. 3 (2023), s. 1201-1209. ISSN 1359-4184. E-ISSN 1476-5578
R&D Projects: GA MZd(CZ) NU21-08-00432
Institutional support: RVO:67985807
Keywords : schizophrenia * neuroimaging * psychiatry * ageing
OECD category: Neurosciences (including psychophysiology
Impact factor: 11, year: 2022
Method of publishing: Open access
https://dx.doi.org/10.1038/s41380-022-01897-w

Schizophrenia (SZ) is associated with an increased risk of life-long cognitive impairments, age-related chronic disease, and premature mortality. We investigated evidence for advanced brain ageing in adult SZ patients, and whether this was associated with clinical characteristics in a prospective meta-analytic study conducted by the ENIGMA Schizophrenia Working Group. The study included data from 26 cohorts worldwide, with a total of 2803 SZ patients (mean age 34.2 years, range 18–72 years, 67% male) and 2598 healthy controls (mean age 33.8 years, range 18–73 years, 55% male). Brain-predicted age was individually estimated using a model trained on independent data based on 68 measures of cortical thickness and surface area, 7 subcortical volumes, lateral ventricular volumes and total intracranial volume, all derived from T1-weighted brain magnetic resonance imaging (MRI) scans. Deviations from a healthy brain ageing trajectory were assessed by the difference between brain-predicted age and chronological age (brain-predicted age difference [brain-PAD]). On average, SZ patients showed a higher brain-PAD of +3.55 years (95% CI: 2.91, 4.19, I2 = 57.53%) compared to controls, after adjusting for age, sex and site (Cohen’s d = 0.48). Among SZ patients, brain-PAD was not associated with specific clinical characteristics (age of onset, duration of illness, symptom severity, or antipsychotic use and dose). This large-scale collaborative study suggests advanced structural brain ageing in SZ. Longitudinal studies of SZ and a range of mental and somatic health outcomes will help to further evaluate the clinical implications of increased brain-PAD and its ability to be influenced by interventions.
Permanent Link: https://hdl.handle.net/11104/0338310